Is Chemed (CHE) Cheap As Investors Revisit Its Hospice Growth Story?

Chemed (CHE) drew fresh attention after its shares closed at US$507.50 on 2 October 2026, posting a 0.91% gain that contrasted with softer recent short term returns.

For context, Chemed’s 0.91% 1 day share price gain comes after a softer 7 day move and a 3.15% 30 day share price decline. However, the year to date share price return of 19.75% and 1 year total shareholder return of 15.04% still suggest that longer term momentum has held up better than very recent trading implies.

Scan how Chemed compares with other resilient operators by reviewing a hand picked 31 resilient stocks with low risk scores that have kept risk scores in check while still offering market exposure.

For Chemed, a modest single-day lift after weaker recent weeks can point to either fresh confidence in hospice and plumbing cash flows or just a mood swing in the market. The valuation work shows which story fits.

Most Popular Narrative: 22% Undervalued

Chemed’s most followed narrative pegs fair value at $650 per share, comfortably above the latest $507.50 close. This puts the focus squarely on how its two core businesses are expected to earn that gap.

An aging US population and management’s intention to pursue additional hospice starts and acquisitions in certificate of need states increase the long term demand pool for VITAS services, which can support sustained growth in average daily census, revenue and earnings.

See why 2 investors see Chemed as 22% undervalued.

Result: Fair Value of $650 (UNDERVALUED)

Still, Chemed’s story can change quickly if Medicare cap exposure resurfaces in larger hospice programs or if Roto Rooter’s paid digital leads remain structurally more expensive.

Find out about the key risks to this Chemed narrative.

Next Steps

Mixed signals around Chemed’s valuation and risk profile make this a decision point for you, not the market narrative. Move quickly, review the underlying numbers, and weigh both sides by checking the 3 key rewards and 1 important warning sign.

Looking for more ideas beyond Chemed?

If Chemed has your attention, do not stop here. Broaden your watchlist, pressure test your convictions, and give yourself options before the next move hits.

• Target income stability by reviewing a hand picked list of 7 dividend fortresses that focus on robust payouts and resilient cash flows.
• Spot potential mispricings early by scanning the 31 high quality undervalued stocks that pair quality fundamentals with prices that still lag underlying business strength.
• Get ahead of the crowd by tracking a curated 19 high quality undiscovered gems that have strong numbers yet limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com